氟西汀在限制型及限制-清除型神经性厌食症中的双盲安慰剂对照给药。
Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa.
作者信息
Kaye W H, Nagata T, Weltzin T E, Hsu L K, Sokol M S, McConaha C, Plotnicov K H, Weise J, Deep D
机构信息
Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
出版信息
Biol Psychiatry. 2001 Apr 1;49(7):644-52. doi: 10.1016/s0006-3223(00)01013-1.
BACKGROUND
Anorexia nervosa is an often chronic disorder with high morbidity and mortality. Many people relapse after weight restoration. This study was designed to determine whether a selective serotonin reuptake inhibitor would improve outcome and reduce relapse after weight restoration by contributing to maintenance of a healthy normal weight and a reduction of symptoms.
METHODS
We administered a double-blind placebo-controlled trial of fluoxetine to 35 patients with restricting-type anorexia nervosa. Anorexics were randomly assigned to fluoxetine (n = 16) or a placebo (n = 19) after inpatient weight gain and then were observed as outpatients for 1 year.
RESULTS
Ten of 16 (63%) subjects remained on fluoxetine for a year, whereas only three of 19 (16%) remained on the placebo for a year (p =.006). Those subjects remaining on fluoxetine for a year had reduced relapse as determined by a significant increase in weight and reduction in symptoms.
CONCLUSIONS
This study offers preliminary evidence that fluoxetine may be useful in improving outcome and preventing relapse of patients with anorexia nervosa after weight restoration.
背景
神经性厌食症是一种常为慢性的疾病，发病率和死亡率都很高。许多人在体重恢复后会复发。本研究旨在确定选择性5-羟色胺再摄取抑制剂是否有助于维持健康的正常体重和减轻症状，从而改善体重恢复后的预后并降低复发率。
方法
我们对35例限制型神经性厌食症患者进行了一项氟西汀的双盲安慰剂对照试验。厌食症患者在住院体重增加后被随机分配到氟西汀组（n = 16）或安慰剂组（n = 19），然后作为门诊患者观察1年。
结果
16名受试者中有10名（63%）服用氟西汀达一年，而19名受试者中只有3名（16%）服用安慰剂达一年（p = 0.006）。通过体重显著增加和症状减轻确定，服用氟西汀达一年的受试者复发率降低。
结论
本研究提供了初步证据，表明氟西汀可能有助于改善神经性厌食症患者体重恢复后的预后并预防复发。
Zotero 插件